Key Highlights

  • GeneDx fell to around $71.60 with no company-specific news, moving lower alongside other diagnostics and genetic-testing companies.
  • The company provides genetic testing, including exome and genome sequencing, used to diagnose rare diseases in children.
  • Illumina, Quest Diagnostics, Danaher and Thermo Fisher all fell the same day as health care was the only losing sector.
  • Pacific Biosciences and Qiagen stood out as exceptions, rising on specific company and analyst news.

GeneDx (NASDAQ:WGS) fell on Tuesday, October 6, trading around $71.60. No company-specific news was found to explain the decline. The stock moved lower alongside other diagnostics and genetic-testing companies as health care lagged the rest of the market.

GeneDx provides genetic testing, including exome and genome sequencing, used to help diagnose rare diseases, particularly in children and newborns. Its results depend on how widely doctors order these tests and how insurers cover them, while its shares often move with sentiment toward the broader diagnostics and genomics space.

The company is a member of the Russell 2000 benchmark of smaller companies.

A Sector-Wide Retreat

Health care was the only major sector to decline on Tuesday. Diagnostics and tools stocks were a particular weak spot. Illumina (NASDAQ:ILMN), whose sequencing machines are widely used in genetic testing, slid after hitting a 52-week high, in what was described as a technical pullback. Quest Diagnostics (NYSE:DGX), Danaher (NYSE:DHR) and Thermo Fisher (NYSE:TMO) also fell.

Smaller peers followed the larger names lower. GRAIL (NASDAQ:GRAL) and Bruker (NASDAQ:BRKR) moved lower without company-specific news, and only 48 of 428 Russell 2000 health-care holdings advanced on the day.

The weakness was not universal. Pacific Biosciences (NASDAQ:PACB), another sequencing company, soared after announcing an RNA data collaboration with TychoBio. Barclays also upgraded diagnostics firm Qiagen (NYSE:QGEN) to Overweight. But those gains stood out precisely because most of the group was falling.

Genetic-testing companies have attracted interest as sequencing costs have fallen and more doctors order genomic tests, but the group remains sensitive to questions about reimbursement and competition.

When an entire sector moves together without specific news, it often reflects investors shifting money between themes. On Tuesday, that rotation favored utilities, AI-linked chip and networking stocks, and software, which hit its highest levels of 2026.

A Market at Records

The broader market was strong. The S&P 500 rose 44.98 points to a record 7,818.93, the Nasdaq Composite closed at a record just under 27,600, and the Dow Jones Industrial Average gained 253.38 points to 51,521.28. The small-cap Russell 2000 slipped roughly 16 to 17 points to about 2,830, with weakness in health care contributing.

Leadership came from Constellation Energy's (NASDAQ:CEG) 20-year nuclear power deal with Google (NASDAQ:GOOGL), which lifted utilities, and from upbeat AI commentary, including Marvell Technology's (NASDAQ:MRVL) higher Revenue outlook.

Bond markets offered some relief. Treasury yields eased, with the 10-year ending near 5.28. Higher rates can weigh on growth companies such as GeneDx, whose valuations are tied to expectations for future earnings.

Reimbursement Trends Will Shape the Rebound

Investors will watch whether the diagnostics pullback continues or reverses in the coming sessions. For GeneDx, test volumes, reimbursement trends, insurance coverage and its next quarterly results will be key markers.